Axxcess Wealth Management LLC Has $226,000 Position in Natera, Inc. (NASDAQ:NTRA)

Axxcess Wealth Management LLC lowered its holdings in Natera, Inc. (NASDAQ:NTRA) by 29.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,425 shares of the medical research company’s stock after selling 601 shares during the period. Axxcess Wealth Management LLC’s holdings in Natera were worth $226,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of NTRA. Wellington Management Group LLP raised its position in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. raised its position in shares of Natera by 25.2% during the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after acquiring an additional 269,706 shares during the last quarter. Castle Hook Partners LP raised its position in shares of Natera by 27.4% during the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock worth $144,734,000 after acquiring an additional 245,505 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Natera by 42.6% during the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after acquiring an additional 328,375 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 792 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $115,663.68. Following the completion of the transaction, the chief financial officer now directly owns 71,869 shares of the company’s stock, valued at approximately $10,495,748.76. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John Fesko sold 669 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the transaction, the insider now directly owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 307,466 shares of company stock valued at $49,047,655 over the last three months. Company insiders own 7.60% of the company’s stock.

Natera Stock Up 1.0 %

NTRA stock opened at $151.15 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market capitalization of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80. The business has a 50-day moving average of $161.23 and a 200-day moving average of $149.75. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTRA. The Goldman Sachs Group boosted their target price on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. BTIG Research reiterated a “buy” rating on shares of Natera in a report on Friday, February 28th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday. Robert W. Baird upped their price objective on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.